Literature DB >> 6817779

An alternative role for specific antibody in neutrophil bactericidal activity against highly pathogenic group B streptococci.

P H Cleat, C R Coid.   

Abstract

An investigation was undertaken into the role of antibody and complement in neutrophil phagocytosis and killing of group B streptococci of low and high pathogenicity. Phagocytosis of both types of organism appears to be a nonspecific event requiring only nonspecific antibody or complement. However, neutrophil bactericidal activity is mediated by the pathogenicity of the infecting organism. Neutrophils alone can kill some streptococci of low pathogenicity, but their killing ability is considerably increased in the presence of specific antibody or complement. An active role for the alternative pathway of complement in the killing process was demonstrated for organisms of low pathogenicity. Neutrophils did not kill the highly pathogenic organisms in the absence of antibody and complement, and required specific antibody, but not complement, to kill these bacteria. The alternative complement pathway is not involved in killing of highly pathogenic organisms. Addition of specific antibody to neutrophils containing ingested bacteria stimulated the neutrophils to kill the intracellular bacteria, suggesting an alternative role for specific antibody in the killing process other than as an opsonin. It is suggested that activation of Fc receptors on the neutrophil surface initiates the bactericidal action of the neutrophils.

Mesh:

Substances:

Year:  1982        PMID: 6817779      PMCID: PMC2040641     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  13 in total

1.  Strain specificity of opsonins for group B streptococci types II and III.

Authors:  A O Shigeoka; R T Hall; H R Hill
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

Review 2.  The Fc-receptor: its role in the transmission of differentiation signals.

Authors:  E Kölsch; J Oberbarnscheidt; K Brüner; J Heuer
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

3.  Protection of mice against group B Streptococcus type Ia by IgG components of a rabbit antiserum.

Authors:  P H Cleat; C R Coid
Journal:  Med Microbiol Immunol       Date:  1980       Impact factor: 3.402

4.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

5.  Antibody levels in mothers colonised with group B streptococci during pregnancy and in their newborn infants, as measured by an enzyme linked immunosorbent assay.

Authors:  P H Cleat; J Ross; J R Needham
Journal:  Med Microbiol Immunol       Date:  1980-02       Impact factor: 3.402

6.  B-lymphocytes activation by the Fc region of IgG.

Authors:  M A Berman; W O Weigle
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

7.  Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens.

Authors:  R C Lancefield; M McCarty; W N Everly
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

8.  Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.

Authors:  G W Fischer; G H Lowell; M H Crumrine; J W Bass
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

9.  The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus.

Authors:  M S Edwards; A Nicholson-Weller; C J Baker; D L Kasper
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

Review 10.  Antibody-mediated destruction of virus-infected cells.

Authors:  J G Sissons; M B Oldstone
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

View more
  1 in total

1.  The mode of action of antibody in neutrophil bactericidal activity against highly pathogenic group-B streptococci.

Authors:  P H Cleat; C R Coid
Journal:  Med Microbiol Immunol       Date:  1984       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.